Out in the Light

During the first six months of 2009, Pfizer paid about $20 million to some 4,500 medical professionals in consulting and speaking fees, reports the New York Times. In addition, Pfizer paid $15.3 million to 250 academic medical centers for clinical trials. These details were released as part of an agreement Pfizer made with the US government during an investigation into the company's promotion of drugs for off-label uses. Eli Lilly, Merck, and GlaxoSmithKline have made similar disclosures.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.